Notably, we assayed serum biomarkers before the advent and validations of various phospho(p)-tau assays; future studies examining these neurodegenerative and neuroinflammation biomarkers and the amyloid and latest p-tau species in plasma, which are more specific to AD pathways, could validate and provide further complementary evidence specific to the AD neurodegenerative process. This evidence concerns the gene MAPT and Alzheimer disease.